✦ LIBER ✦

Economic and regulatory considerations in pharmacogenomics for drug licensing and healthcare

✍ Scribed by Shah, Jai

Book ID: 109905255
Publisher: Nature Publishing Group
Year: 2003
Tongue: English
Weight: 156 KB
Volume: 21
Category: Article
ISSN: 1087-0156
DOI: 10.1038/nbt0703-747

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Pharmacogenomics: a new clinical or regu

Pharmacogenomics: a new clinical or regulatory paradigm? European experiences of pharmacogenomics in drug regulation and regulatory initiatives

✍ Krishna Prasad; Alasdair Breckenridge 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 732 KB

Pharmacogenetics in drug development: Re

Pharmacogenetics in drug development: Regulatory and clinical considerations

✍ Susan T. Hall; Neil Abbott; Ginny Schmith; Celia Brazell 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 102 KB

Using pharmacogenetics and pharmacogenom

Using pharmacogenetics and pharmacogenomics in the treatment of psychiatric disorders: some ethical and economic considerations

✍ KatherineI. Morley; WayneD. Hall 📂 Article 📅 2004 🏛 Springer 🌐 English ⚖ 214 KB

Institutional Profile: Jayne Haines Cent

Institutional Profile: Jayne Haines Center for Pharmacogenomics and Drug Safety: educating future generations of healthcare professionals

✍ Krynetskiy, Evgeny 📂 Article 📅 2013 🏛 Future Medicine 🌐 English ⚖ 471 KB

Scientific considerations for complex dr

Scientific considerations for complex drugs in light of established and emerging regulatory guidance

✍ Holloway, Chris; Mueller-Berghaus, Jan; Lima, Beatriz Silva; Lee, Sau Larry; Wya 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 182 KB

Drug Repositioning (Bringing New Life to

Drug Repositioning (Bringing New Life to Shelved Assets and Existing Drugs) || Regulatory Considerations and Strategies for Drug Repositioning

✍ Barratt, Michael J.; Frail, Donald E. 📂 Article 📅 2012 🏛 John Wiley & Sons, Inc. 🌐 English ⚖ 175 KB

Drug Repositioning : The Business Case And Current Strategies To Repurpose Shelved Candidates And Marketed Drugs / John Arrowsmith And Richard Harrison -- Opportunities And Challenges Associated With Developing Additional Indications For Clinical Development Candidates And Marketed Drugs / Donald E.